Clinical subject area

The BSRBRs have been publishing academic output for nearly fifteen years. Below are the published academic papers categorised by clinical subjects.


The Registers' systematic collection and analysis of large amounts of patient data traces the effects of biologics drugs in long term use. In addition, a large number of poster and oral presentations have also been given in the UK, Europe and internationally. The majority of these papers are from the RA Register. The AS register is far younger and its data is still maturing.


Thousands of people - patients, health professionals, managers, administrators and pharmaceutical sponsors have all contributed to creating this output. BSR is proud to be part of that partnership.

Most of the papers are available for FREE via open access. A 'DOI' - Digital Object Identifier - has been included to help locate the paper, simply copy and paste 'DOI' + its number as listed into the URL address bar and tap return. One of the top items will almost certainly link you directly to the paper you want.

Below are the clinical subjects


Cancer | Serious Infections | Fatigue | Mortality | Clot | Pregnancy | Other risks | Misc social |




Cancer

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register
Rheumatoid Arthritis
Lucía Silva-Fernández et al Rheumatology (2016) doi: 10.1093/rheumatology/kew314 First published online: August 22 2016

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
Louise K Mercer et al Ann Rheum Dis Published Online First: 15 June 2016 doi:10.1136/annrheumdis-2016-209285

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer, L., Lunt, M., Low, A., Dixon, W., Watson, K., Symmons, D. & Hyrich, K.
2015 Ann Rheum Dis. Jun;74(6):1087-93. doi:10.1136/annrheumdis-2013-204851

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
Mercer, L., Davies, R., Galloway, J., Low, A., Lunt, M., Dixon, W., Watson, K., Symmons, D., Hyrich, K. & BSRBR Control Centre Consortium.
2013 Rheumatology (Oxford), 52(1), 91-98. DOI:10.1093/rheumatology/kes350

Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix.
Mercer, L., Low, A., Galloway, J., Watson, K., Lunt, M., Symmons, D., Hyrich, K. & BSRBR Control Centre-Consortium.
2013 Ann Rheum Dis, 72(1), 143-144. DOI:10.1136/annrheumdis-2012-201814

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
Mercer, L., Green, A., Galloway, J., Davies, R., Lunt, M., Dixon, W., Watson, K., BSRBR Control Centre Consortium, B., Symmons, D., Hyrich, K. & BSR Biologics Register, B
2012 Annals of the Rheumatic Diseases 71(6), 869-874. DOI:10.1136/annrheumdis-2011-200622

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register.
Dixon, W., Watson, K., Lunt, M., Mercer, L., Hyrich, K., Symmons, D.
& BSRBR Control Centre Consortium, B
2010 Arthritis Care Res (Hoboken), 62(6), 755-63. DOI:10.1002/acr.20129

Back to top

Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from BSR's Biologics Register for Rheumatoid Arthritis
Ellen S. Bruce, Lianne Kearsley-Fleet, Kath D. Watson, Deborah P. M. Symmons, and Kimme L. Hyrich [LETTER] Rheumatology published 26 April 2016, 10.1093/rheumatology/kew200

Risk of
skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Galloway, J., Mercer, L., Moseley, A., Dixon, W., Ustianowski, A., Helbert, M., Watson, K., Lunt, M., Hyrich, K. & Symmons, D.
2013 Ann Rheum Dis, 72(2), 229-234. DOI:10.1136/annrheumdis-2011-201108

The
risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register.
2011 Rheumatology, 50(7), 1341-1342. DOI:10.1093/rheumatology/ker146

Anti-TNF therapy is associated with an increased
risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Galloway, J., Hyrich, K., Mercer, L., Dixon, W., Fu, B., Ustianowski, A., Watson, K., Lunt, M., BSR Control Centre Consortium, B., Symmons, D.
& BSR Biologics Register, B
2011 Rheumatology (Oxford), 50(1), 124-131. DOI:10.1093/rheumatology/keq242

Risk of
septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
Galloway, J., Hyrich, K., Mercer, L., Dixon, W., Ustianowski, A., Helbert, M., Watson, K., Lunt, M., Symmons, D. & BSR Biologics Register, B
2011 Ann Rheum Dis, 70(10), 1810-1814. DOI:10.1136/ard.2011.152769

Drug-specific risk of
tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
Dixon, W., Hyrich, K., Watson, K., Lunt, M., Galloway, J., Ustianowski, A., BSR Control Centre Consortium, B. & Symmons, D
2010 Annals of the rheumatic diseases, 69(3), 522. DOI:10.1136/ard.2009.118935

Serious infection
following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.
Dixon WG, Symmons D, Lunt M, Watson KD, Hyrich KL, Silman AJ.
2007 Arthritis Rheum, 56( 9), 2896-904. 10.1002/art.22808

Rates of
serious infection , including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register.
Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons D.
2006 Arthritis and Rheumatism, 54, 8, 2368-2376. DOI:10.1002/art.21978

Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Katie L. Druce et al Rheumatology (2016) doi: 10.1093/rheumatology/kew241 First published online: June 21, 2016

The changes in pain which mediate reductions in fatigue likely reflect central not peripheral mechanisms. Results from the BSRBR-RA.
Katie L Druce, Gareth T Jones, Gary J Macfarlane, Neil Basu
2015 Arthritis Care and Research 25 Nov 2015 DOI:10.1002/acr.22803.

Determining pathways to improvements in fatigue in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Druce KL, Jones GT,  Macfarlane GJ, Basu N
2015 Arthritis & Rheumatology Vol. 67, No. 9, September 2015, pp 2303–2310 DOI 10.1002/art.39238

Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Druce KL, Jones GT, Macfarlane GJ, Basu N
2015 Rheumatology  54 (6): 964-971 doi:10.1093/rheumatology/keu390


No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register.
Lunt, M., Watson, K., Dixon, W., Symmons, D., Hyrich, K., BSR Control Centre Consortium, B. & BSR Biologics Register, B
2010 Arthritis and Rheumatism, 62(11), 3145-3153. DOI:10.1002/art.27660


Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis

Audrey SL Low, Deborah P M Symmons, Mark Lunt, Louise K Mercer, Chris P Gale,Kath D Watson, William G Dixon, Kimme L Hyrich, on behalf of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBRRA) and the BSRBR Control Centre Consortium. Ann Rheum Dis Published Online First: 10 January 2017 doi:10.1136/annrheumdis-2016-209784


Association between ischaemic stroke and tumour necrosis factor inhibitor therapy in patients with

rheumatoid arthritis.

 

Audrey SL Low, Mark Lunt, Louise K Mercer, Kath D Watson, William G Dixon, Deborah PM Symmons,

Kimme L Hyrich

 

2016 Arthritis & Rheumatology accepted article DOI 10.1002/art.39582

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
Davies, R., Galloway, J., Watson, K., Lunt, M., Symmons, D., Hyrich, K., BSRBR Control Centre Consortium, B. & BSR Biologics Register, 2011 Ann Rheum Dis, 70(10), 1831-4. DOI:10.1136/ard.2011.153536

Reduction in the incidence of
myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons D.
2007 Arthritis Rheum, 56( 9), 2905-12. DOI: 10.1002/art.22809

 



Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. [LETTER]
Diederik De Cock, Lucy Birmingham, Kath D. Watson, Lianne Kearsley-Fleet, BSRBR Control Centre Consortium, Deborah P. Symmons, Kimme L. Hyrich
Rheumatology (Oxford) 2017 kew493. doi: 10.1093/rheumatology/kew493

Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.
Verstappen, S., King, Y., Watson, K., Symmons, D. & Hyrich, K
2011 Annals of the rheumatic diseases, 70(5), 823-826. DOI:10.1136/ard.2010.140822

Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: Results from a national population register.
Hyrich KL, Symmons D, Watson KD, Silman AJ.
2006 Arthritis and Rheumatism, 54, 8, 2701-2702. DOI: 10.1002/art.22028


 

Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
Daniel F. McWilliams and David A. Walsh BMC Musculoskeletal Disorders (2016) 17:337  DOI 10.1186/s12891-016-1192-7

The risk of
gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.
Závada, J., Lunt, M., Davies, R., Low, A., Mercer, L., Galloway, J., Watson, K., Symmons, D., Hyrich, K.
2014 Ann Rheum Dis, 73(1), 252-255. DOI:10.1136/annrheumdis-2012-203102

Treatment of rheumatoid arthritis with etanercept with reference to
disease-modifying anti-rheumatic drugs : long-term safety and survival using prospective observational data
Morgan, C.L., Emery P., Porter D., Reynolds A., Young A., Boyd H., Poole CD., Currie CJ
2014 Rheumatology (Oxford), 53(1), 186-94 doi: 10.1093/rheumatology/ket333

Influence of anti-TNF therapy on mortality in patients with
rheumatoid arthritis-associated interstitial lung disease : results from the British Society for Rheumatology Biologics Register.
Dixon, W., Hyrich, K., Watson, K., Lunt, M., BSRBR Control Centre Consortium, B. & Symmons, D
2010 Annals of the Rheumatic Diseases, 69(6), 1086-1091. DOI:10.1136/ard.2009.120626

Rates of
new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNFα therapy. Harrison MJ, Dixon WG, Watson KD, King YE, Groves R, Hyrich KL, Symmons D, BSRBR Control Centre Consortium.
2009 Ann Rheum Dis, 68(2), 209-215. DOI:10.1136/ard.2007.087288


Does sex or ethnicity impact anti-tumour necrosis factor agent use in rheumatoid arthritis? 
Elaine M Dennison, Karen A Jameson, Jonathan Marks, Kath Watson, Kimme Hyrich, Deborah Symmons and Cyrus Cooper. [LETTER] Rheumatology (2016) doi: 10.1093/rheumatology/kew466


Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.
Saad, A., Ashcroft, D., Watson, K., Symmons, D., Noyce, P. & Hyrich, K
2010 Arthritis Care Res (Hoboken), 62(3), 345-53. DOI:10.1002/acr.20104

Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.
Verstappen, S., Watson, K., Lunt, M., McGrother, K., Symmons, D., Hyrich, K. & BSR Biologics Register, B
2010 Rheumatology, 49(8), 1570-1577. DOI:10.1093/rheumatology/keq131

The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era.
Morgan C., McBeth J., Cordingley L., Watson K., Hyrich KL., Symmons DP., Bruce IN.
2015 Rheumatology (Oxford). Oct; 54(10):1780-91. doi: 10.1093/rheumatology/kev105